In this ninth edition of DDI of the Month, host Prof. dr. David Burger welcomes two leading experts from Switzerland, Dr Claire Coumau and Dr Chantal Csajka, for an in-depth discussion on P-glycoprotein (P-gp)–mediated drug–drug interactions. The episode is centered around their recent publication in Clinical Pharmacokinetics: “A Systematic Review and Classification of the Effects of P-glycoprotein Inhibitors and Inducers in Humans, Using Digoxin, Fexofenadine, and Dabigatran as Probe Drugs.”...
All content for DDI of the Month Podcast is the property of Global DDI Solutions and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
In this ninth edition of DDI of the Month, host Prof. dr. David Burger welcomes two leading experts from Switzerland, Dr Claire Coumau and Dr Chantal Csajka, for an in-depth discussion on P-glycoprotein (P-gp)–mediated drug–drug interactions. The episode is centered around their recent publication in Clinical Pharmacokinetics: “A Systematic Review and Classification of the Effects of P-glycoprotein Inhibitors and Inducers in Humans, Using Digoxin, Fexofenadine, and Dabigatran as Probe Drugs.”...
In this ninth edition of DDI of the Month, host Prof. dr. David Burger welcomes two leading experts from Switzerland, Dr Claire Coumau and Dr Chantal Csajka, for an in-depth discussion on P-glycoprotein (P-gp)–mediated drug–drug interactions. The episode is centered around their recent publication in Clinical Pharmacokinetics: “A Systematic Review and Classification of the Effects of P-glycoprotein Inhibitors and Inducers in Humans, Using Digoxin, Fexofenadine, and Dabigatran as Probe Drugs.”...
DDI of the Month returns with Episode 8! Tune in as we explore new data on the metamizole-quetiapine interaction and its clinical impact. In this episode of DDI of the Month, we’re excited to welcome two distinguished quests from Germany: Dr. Arnim Gaebler and Dr. Michael Paulzen. Together, we dive into their recent published paper in the British Journal of Clinical Pharmacology, titled: “Discovering interactions in polypharmacy: Impact of metamizole on the metabolism of quetiapine” M...
In the seventh episode, Prof. Dr. David Burger discusses with Nicki Kyriacou the review article: “Green tea catechins as perpetrators of drug pharmacokinetic interactions”. You might think: “Green tea?– I drink it all the time! “But is it really that innocent? Tune in now as we explore how catechins-compounds found in green tea, like (-)-epigallocatechin-3-gallate – can impact drug pharmacokinetics. These compounds can alter drug solubility, transporter activity, and metabolism, potenti...
In this episode of the DDI of the Month podcast, Dr. David Burger dives into a critical topic: P-glycoprotein (P-gp)-mediated Drug-Drug Interactions with Dr. Leonie Bogaard. Join us as we explore the role of P-gp, a key transporter involved in drug absorption and elimination, and its impact on clinical outcomes. In this episode, we discuss: • How P-gp modulation affects systemic drug exposure. • The challenges in managing DDIs due to overlap with enzymes like CYP3A4....
In our latest episode, we dive into an important study by Dr. Massimo and Dr. Gianluca which examins the agreement between different drug interaction checkers (ICs) when evaluating interactions involving widely used proton pump inhibitors (PPIs). PPIs are frequently prescribed for treating acid-related conditions and preventing medication-induced ulcers, especially in older patients with multimorbidity and polypharmacy. These interactions are often complex, involving increased gastric ...
The fourth episode will delve into the use of artificial intelligence (AI) to optimize medication alerts generated by clinical decision support systems (CDSSs). David Burger will discuss the review findings and future opportunities with Jetske Graafsma and Dr. Patricia van den Bemt. Medication safety is crucial, and preventing adverse drug events (ADEs) is a key aspect. Clinical decision support systems (CDSSs) in electronic health records help reduce the risk of ADEs by generating ale...
In the third podcast, Dr. Burger discusses the added value of reporting outcomes of real-world cases in patients with HIV caused by drug-drug interactions (DDIs) with Dr. Ambrosioni and Dr. Molto. Several databases are available for DDI management, with discrepancies often occurring between the databases. The differences may be caused by extrapolations from studied interactions to predict the DDI potential for unknown drug combinations. The relevance of the unstudied DDIs is often unknown. ...
In the second episode of this podcast series, Dr. Malone, Dr. Gómez-Lumbreras, and Dr. Burger will discuss the drug-drug interaction potential of colchicine, which may be underestimated. Dr. Malone’s research group did a study on real-world data on the interaction potential of colchicine. Colchicine concentration can be increased by CYP3A4 inhibitors, which may lead to toxicity and adverse events. Adverse events cases reported between 2004 and 2020 were studied for the involvement of co...
In the first exciting episode of this new podcast series, Dr. Iversen and Dr. Burger will dive into DDIs with flucloxacillin, and explore the results of Dr. Iversen's research trial. Dr. Iversen’s research group has studied the extent of induction of flucloxacillin of the CYP enzymes in healthy adults and 3D spheroid of primary human hepatocytes (PHHs). The research group performed a randomized, unblinded, two-period, cross-over, clinical pharmacokinetic (Basel) cocktail study with twelve he...
In this ninth edition of DDI of the Month, host Prof. dr. David Burger welcomes two leading experts from Switzerland, Dr Claire Coumau and Dr Chantal Csajka, for an in-depth discussion on P-glycoprotein (P-gp)–mediated drug–drug interactions. The episode is centered around their recent publication in Clinical Pharmacokinetics: “A Systematic Review and Classification of the Effects of P-glycoprotein Inhibitors and Inducers in Humans, Using Digoxin, Fexofenadine, and Dabigatran as Probe Drugs.”...
